Identification of Novel Plasma Biomarkers for Abdominal Aortic Aneurysm by Protein Array Analysis

Jianqiang Wu,Wei Wang,Ting Xie,Zhaoran Chen,Lei Zhou,Xiaohong Song,Haoxuan Kan,Yanze Lv,Lianglin Wu,Fangda Li,Dan Yang,Yuexin Chen,Bao Liu,Yuehong Zheng
DOI: https://doi.org/10.3390/biom12121853
IF: 6.064
2022-12-13
Biomolecules
Abstract:Abdominal aortic aneurysm (AAA) is a potentially life-threatening disease that is common in the aging population. Currently, there are no approved diagnostic biomarkers or therapeutic drugs for AAA. We aimed to identify novel plasma biomarkers or potential therapeutic targets for AAA using a high-throughput protein array-based method. Proteomics expression profiles were investigated in plasma from AAA patients and healthy controls (HC) using 440-cytokine protein array analysis. Several promising biomarkers were further validated in independent cohorts using enzyme-linked immunosorbent assay (ELISA). Thirty-nine differentially expressed plasma proteins were identified between AAA and HC. Legumain (LGMN) was significantly higher in AAA patients and was validated in another large cohort. Additionally, "AAA without diabetes" (AAN) patients and "AAA complicated with type 2 diabetes mellitus" (AAM) patients had different cytokine expression patterns in their plasma, and nine plasma proteins were differentially expressed among the AAN, AAM, and HC subjects. Delta-like protein 1 (DLL1), receptor tyrosine-protein kinase erbB-3 (ERBB3), and dipeptidyl peptidase 4 (DPPIV) were significantly higher in AAM than in AAN. This study identified several promising plasma biomarkers of AAA. Their role as therapeutic targets for AAA warrants further investigation.
biochemistry & molecular biology
What problem does this paper attempt to address?